RS52144B - OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR - Google Patents

OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR

Info

Publication number
RS52144B
RS52144B YU92303A YUP92303A RS52144B RS 52144 B RS52144 B RS 52144B YU 92303 A YU92303 A YU 92303A YU P92303 A YUP92303 A YU P92303A RS 52144 B RS52144 B RS 52144B
Authority
RS
Serbia
Prior art keywords
solution
enantiomer
compound
methylpiperidin
pyrrolo
Prior art date
Application number
YU92303A
Other languages
English (en)
Serbian (sr)
Inventor
Mark Edward Flanagan
Glenn Ernest Wilcox
Christian Koecher
Ton Vries
Michael John Munchhof
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52144(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU92303A publication Critical patent/YU92303A/sh
Publication of RS52144B publication Critical patent/RS52144B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
YU92303A 2001-05-31 2002-05-29 OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR RS52144B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US34104801P 2001-12-06 2001-12-06

Publications (2)

Publication Number Publication Date
YU92303A YU92303A (sh) 2006-08-17
RS52144B true RS52144B (en) 2012-08-31

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
YU92303A RS52144B (en) 2001-05-31 2002-05-29 OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR

Country Status (52)

Country Link
US (2) US7301023B2 (instruction)
EP (3) EP1666481B9 (instruction)
JP (1) JP4381137B2 (instruction)
KR (5) KR100926875B1 (instruction)
CN (1) CN1729192A (instruction)
AP (1) AP1859A (instruction)
AR (2) AR037321A1 (instruction)
AT (1) ATE519741T1 (instruction)
AU (2) AU2002304401C1 (instruction)
BE (1) BE2017C032I2 (instruction)
BG (1) BG66489B1 (instruction)
BR (1) BR0209246A (instruction)
CA (1) CA2448281C (instruction)
CL (1) CL2008000762A1 (instruction)
CR (1) CR10177A (instruction)
CU (1) CU23337B7 (instruction)
CY (2) CY1113322T1 (instruction)
CZ (1) CZ304366B6 (instruction)
DK (1) DK1666481T3 (instruction)
EA (2) EA007251B1 (instruction)
EC (1) ECSP034865A (instruction)
EE (1) EE05332B1 (instruction)
ES (2) ES2369226T3 (instruction)
FR (1) FR17C1031I2 (instruction)
GE (1) GEP20063784B (instruction)
GT (2) GT200200100AA (instruction)
HR (1) HRP20030943B1 (instruction)
HU (2) HU230876B1 (instruction)
IL (1) IL158588A0 (instruction)
IS (1) IS3023B (instruction)
LT (1) LTC1666481I2 (instruction)
LU (1) LUC00031I2 (instruction)
MA (1) MA27029A1 (instruction)
MX (1) MXPA03011062A (instruction)
MY (1) MY129649A (instruction)
NL (1) NL300887I2 (instruction)
NO (3) NO328578B1 (instruction)
NZ (2) NZ530380A (instruction)
OA (1) OA12612A (instruction)
PA (1) PA8546301A1 (instruction)
PE (1) PE20030561A1 (instruction)
PL (2) PL367945A1 (instruction)
PT (1) PT1666481E (instruction)
RS (1) RS52144B (instruction)
SI (1) SI1666481T1 (instruction)
SK (2) SK288192B6 (instruction)
TN (1) TNSN03128A1 (instruction)
TW (2) TWI310384B (instruction)
UA (1) UA80093C2 (instruction)
UY (1) UY27317A1 (instruction)
WO (1) WO2002096909A1 (instruction)
ZA (1) ZA200307982B (instruction)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
TR200201498T2 (tr) 1999-12-10 2003-01-21 Pfizer Products Inc. Pirrolo [2,3-d] pirimidin bileşikleri.
WO2002000661A1 (en) * 2000-06-26 2002-01-03 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2492325C (en) 2002-07-29 2012-09-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP2005539041A (ja) * 2002-08-27 2005-12-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Rafキナーゼ阻害剤としてのグリシンアミド誘導体
AU2003276591A1 (en) 2002-11-26 2004-06-18 Pfizer Products Inc. Method of treatment of transplant rejection
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
JP2007536310A (ja) * 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト S1p受容体アゴニストおよびjak3キナーゼ阻害剤を含む、組合せ剤
JP2008505088A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド ACK1およびLCK活性を調節するピロロ[2,3−d]ピリミジン
BRPI0514094A (pt) 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
CA2586605A1 (en) * 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2615291A1 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
NZ565363A (en) * 2005-07-29 2010-03-26 Pfizer Prod Inc Pyrrolo[2,3-D]pyrimidine derivatives; their intermediates and synthesis
CA2621261C (en) 2005-09-22 2014-05-20 Incyte Corporation Azepine inhibitors of janus kinases
BRPI0619817B8 (pt) 2005-12-13 2021-05-25 Incyte Corp composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2575797T3 (es) 2007-06-13 2016-07-01 Incyte Holdings Corporation Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
BRPI0813553A2 (pt) * 2007-07-11 2017-05-09 Pfizer composições farmacêuticas e métodos para tratamento de distúrbios do olho seco
JP5711537B2 (ja) 2008-02-15 2015-05-07 ライジェル ファーマシューティカルズ, インコーポレイテッド ピリミジン−2−アミン化合物およびjakキナーゼの阻害剤としてのその使用
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ, インコーポレイテッド タンパク質キナーゼの阻害剤
EP2324020A2 (en) * 2008-08-01 2011-05-25 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as jak3 inhibitors
PL2384326T3 (pl) * 2008-08-20 2014-09-30 Zoetis Services Llc Związki pirolo[2,3-d]pirymidyonowe
JP2012517448A (ja) * 2009-02-11 2012-08-02 リアクション バイオロジー コープ. 選択的キナーゼ阻害剤
CA3025627C (en) 2009-04-20 2021-08-31 Auspex Pharmaceuticals, Inc. Piperidine inhibitors of janus kinase 3
MX2011012353A (es) 2009-05-22 2011-12-14 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2475667A1 (en) * 2009-09-10 2012-07-18 F. Hoffmann-La Roche AG Inhibitors of jak
PL2486041T3 (pl) 2009-10-09 2014-01-31 Incyte Holdings Corp Pochodne hydroksylowe, keto i glukuronidowe 3-(4-(7H-pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo)-3-cyklopentylopropanonitrylu
JP5629324B2 (ja) 2009-10-15 2014-11-19 ファイザー・インク ピロロ[2,3−d]ピリミジン化合物
EP2513114B1 (en) 2009-12-18 2014-04-02 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
WO2011086053A1 (en) * 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
WO2011097087A1 (en) 2010-02-05 2011-08-11 Pfizer Inc. Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
EP4400172A3 (en) 2010-03-10 2024-11-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
SG10201910912TA (en) 2010-05-21 2020-01-30 Incyte Corp Topical Formulation for a JAK Inhibitor
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
JP5936628B2 (ja) 2011-02-18 2016-06-22 ノバルティス・ファルマ・アクチェンゲゼルシャフトNovartis Pharma AG mTOR/JAK阻害剤併用療法
WO2012135338A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Processes for preparing tofacitinib salts
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
SG193245A1 (en) * 2011-04-08 2013-10-30 Pfizer Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8877760B2 (en) 2011-11-23 2014-11-04 Portola Pharmaceuticals, Inc. Substituted pyrazine-2-carboxamide kinase inhibitors
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP2791141B1 (en) 2011-12-15 2017-02-08 ratiopharm GmbH Tofacitinib mono-tartrate salt
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN104837817B (zh) 2012-07-25 2017-03-22 力奇制药公司 制备3‑氨基‑哌啶化合物的合成路线
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
HRP20211158T1 (hr) 2012-11-15 2021-10-15 Incyte Holdings Corporation Oblici za doziranje ruksolitiniba s odgođenim oslobađanjem
WO2014083150A1 (en) * 2012-11-30 2014-06-05 Lek Pharmaceuticals D.D. Preparation of 3-amino-piperidine compounds via nitro-tetrahydropyridine precursors
EP2935216B1 (en) 2012-12-17 2018-06-27 Sun Pharmaceutical Industries Limited Process for the preparation of tofacitinib and intermediates thereof
EP2938616A4 (en) 2012-12-28 2016-06-15 Glenmark Pharmaceuticals Ltd PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
SI2958921T1 (sl) 2013-02-22 2017-12-29 Pfizer Inc. Derivati pirolo(2,3-d)pirimidina kot inhibitorji Janus kinaz (JAK)
SMT201900081T1 (it) 2013-03-06 2019-05-10 Incyte Holdings Corp Procedimenti e intermedi per produrre un inibitore di jak
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
MY195091A (en) 2013-08-07 2023-01-10 Incyte Corp Sustained Release Dosage Forms for a JAK1 Inhibitor
CN104513248B (zh) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 一种托法替尼中间体的纯化方法
JP6192839B2 (ja) 2013-12-05 2017-09-06 ファイザー・インク ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、およびピロロ[2,3−d]ピリジニルアクリルアミド
TR201904767T4 (tr) 2013-12-09 2019-05-21 Unichem Lab Ltd (3R,4R)-(1-benzil-4-metilpiperidin-3-il)-metilamin hazırlanması için geliştirilmiş bir işlem.
CA2881262A1 (en) 2014-02-06 2015-08-06 Prabhudas Bodhuri Solid forms of tofacitinib salts
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
ES2750655T3 (es) 2014-08-12 2020-03-26 Pfizer Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
AU2016208906B2 (en) * 2015-01-20 2018-07-12 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitor
CN106660949B (zh) * 2015-02-17 2020-11-13 株式会社爱茉莉太平洋 N-[4-(1-氨基乙基)-苯基]-磺酰胺衍生物的手性拆分方法
CN104761556B (zh) * 2015-03-21 2017-06-23 河北国龙制药有限公司 托法替布中间体杂质、托法替布杂质及其合成方法,以及托法替布的质量监控方法
EP3078665A1 (en) * 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
KR102006684B1 (ko) 2015-04-29 2019-08-02 우시 포춘 파마슈티컬 컴퍼니 리미티드 Jak 억제제
EP3288943B1 (en) 2015-05-01 2022-09-28 Pfizer Inc. Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase
HUE050842T2 (hu) 2015-05-29 2021-01-28 Wuxi Fortune Pharmaceutical Co Ltd Janus-kináz inhibitor
BR112017013253A2 (pt) * 2015-07-27 2018-02-27 Unichem Laboratories Limited comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
WO2017091681A1 (en) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Selective kinase inhibitors
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20190083609A1 (en) 2016-01-18 2019-03-21 Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) Tofacitinib as vaccination immune modulator
SG11201811470PA (en) 2016-06-30 2019-01-30 Daewoong Pharmaceutical Co Ltd Pyrazolopyrimidine derivatives as kinase inhibitor
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko) 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
RU2758370C1 (ru) 2017-12-28 2021-10-28 Даевунг Фармасьютикал Ко., Лтд. Производные оксифторпиперидина в качестве ингибитора киназы
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
BR112020015470A2 (pt) 2018-01-30 2020-12-08 Incyte Corporation Processos para preparação de (1-(3-fluoro-2-(trifluorometil)isonicotinil)piperidina-4-ona
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
CA3089108A1 (en) * 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
HRP20240741T1 (hr) 2018-03-30 2024-12-06 Incyte Corporation Liječenje hidradenitis suppurativa uporabom jak inhibitora
KR102131107B1 (ko) * 2019-01-15 2020-07-07 주식회사 다산제약 3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
WO2020172714A1 (en) 2019-02-27 2020-09-03 Samson Clinical Pty Ltd Treatment of autoimmune disease
US12269830B2 (en) 2019-03-13 2025-04-08 Intas Pharmaceuticals Ltd. Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
WO2020198583A1 (en) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Bicyclic jak inhibitors and uses thereof
EP3927689B1 (en) * 2019-04-05 2024-01-24 Yuhan Corporation Processes for preparing (3r,4r)-1-benzyl-n,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
CA3161153A1 (en) 2019-11-14 2021-05-20 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
KR20210064093A (ko) 2019-11-25 2021-06-02 주식회사 대웅제약 신규한 트리아졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN115715194A (zh) 2020-04-04 2023-02-24 辉瑞公司 治疗冠状病毒疾病2019的方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022194782A1 (en) * 2021-03-15 2022-09-22 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (nl) * 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JPH07330732A (ja) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd 光学活性な3−アミノ−1−ベンジルピペリジン誘導体
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
ATE247469T1 (de) 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
US6066638A (en) 1995-07-05 2000-05-23 E. I. Du Pont De Nemours And Company Fungicidal pyrimidinones
IL122855A (en) 1995-07-06 2004-08-31 Novartis Ag History of N-Phenyl (Alkyl) - 7H-Pyrolo [-3,2d] Pyrimidine - 4 Amine, their preparation and pharmaceutical preparations containing them
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ES2159760T3 (es) 1995-11-14 2001-10-16 Pharmacia & Upjohn Spa Derivados de aril purina y piridopirimidina y de heteroaril purina y piridopirimidina.
PT888349E (pt) 1996-01-23 2002-10-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69718472T2 (de) 1996-07-13 2003-11-06 Glaxo Group Ltd., Greenford Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
US6180636B1 (en) * 1996-08-23 2001-01-30 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
CN1237177A (zh) 1996-11-27 1999-12-01 辉瑞大药厂 稠合的二环嘧啶衍生物
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-d]피리미딘 및 4-아미노피리미딘
WO1998043087A1 (en) * 1997-03-24 1998-10-01 Pharmacia & Upjohn Company Method for identifying inhibitors of jak2/cytokine receptor binding
CA2326383A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
CA2333392A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
IL139586A0 (en) 1998-06-19 2002-02-10 Pfizer Prod Inc PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS
EP1091739A1 (en) 1998-06-30 2001-04-18 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
ATE292121T1 (de) 1998-08-21 2005-04-15 Parker Hughes Inst Chinazolinderivate
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
TR200201498T2 (tr) * 1999-12-10 2003-01-21 Pfizer Products Inc. Pirrolo [2,3-d] pirimidin bileşikleri.
WO2002000661A1 (en) * 2000-06-26 2002-01-03 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
JP2008505088A (ja) * 2004-06-29 2008-02-21 アムゲン インコーポレイティッド ACK1およびLCK活性を調節するピロロ[2,3−d]ピリミジン

Also Published As

Publication number Publication date
GEP20063784B (en) 2006-04-10
CA2448281C (en) 2009-05-05
CA2448281A1 (en) 2002-12-05
BE2017C032I2 (instruction) 2021-07-19
TWI316061B (en) 2009-10-21
KR100926875B1 (ko) 2009-11-16
EP1392694A1 (en) 2004-03-03
YU92303A (sh) 2006-08-17
GT200200100AA (es) 2007-07-06
AU2008203170A1 (en) 2008-08-07
LTC1666481I2 (lt) 2018-06-25
PT1666481E (pt) 2012-12-03
MA27029A1 (fr) 2004-12-20
JP2004534047A (ja) 2004-11-11
TW200413370A (en) 2004-08-01
LTPA2017025I1 (lt) 2017-09-11
AP2002002550A0 (en) 2002-06-30
AR045680A2 (es) 2005-11-09
NO20035201L (no) 2003-11-24
US7432370B2 (en) 2008-10-07
BR0209246A (pt) 2004-06-15
HUS1900008I1 (hu) 2020-02-28
LUC00031I1 (instruction) 2017-08-10
HU230876B1 (hu) 2018-11-29
FR17C1031I2 (fr) 2018-11-02
CZ304366B6 (cs) 2014-04-02
FR17C1031I1 (fr) 2017-10-13
BG66489B1 (bg) 2015-05-29
EE05332B1 (et) 2010-08-16
NZ530380A (en) 2005-08-26
KR20040003037A (ko) 2004-01-07
SI1666481T1 (sl) 2012-11-30
TNSN03128A1 (fr) 2005-12-23
EP1666481B9 (en) 2013-05-01
SK288199B6 (sk) 2014-06-03
CY2017028I2 (el) 2018-02-14
EE200300594A (et) 2004-04-15
KR20080002931A (ko) 2008-01-04
PL228155B1 (pl) 2018-02-28
EA012666B1 (ru) 2009-12-30
US7301023B2 (en) 2007-11-27
CZ20033260A3 (en) 2004-03-17
AU2008203170B2 (en) 2009-06-18
NZ540332A (en) 2007-05-31
AP1859A (en) 2008-07-02
MY129649A (en) 2007-04-30
CY2017028I1 (el) 2018-02-14
ES2369226T3 (es) 2011-11-28
GT200200100A (es) 2003-02-11
SK14652003A3 (sk) 2004-05-04
HRP20030943A2 (en) 2005-08-31
KR20060014459A (ko) 2006-02-15
KR100868814B1 (ko) 2008-11-14
ES2393385T3 (es) 2012-12-20
HUP0400152A3 (en) 2012-12-28
ATE519741T1 (de) 2011-08-15
AU2002304401B2 (en) 2008-04-17
HUP0400152A2 (en) 2007-07-30
KR100869409B1 (ko) 2008-11-21
NL300887I2 (nl) 2017-08-31
UA80093C2 (uk) 2007-08-27
PA8546301A1 (es) 2003-05-14
CY1113322T1 (el) 2016-06-22
US20040229923A1 (en) 2004-11-18
AU2002304401C1 (en) 2009-03-05
KR20080083028A (ko) 2008-09-12
HRP20030943B1 (hr) 2011-11-30
DK1666481T3 (da) 2012-10-15
US20030073719A1 (en) 2003-04-17
EA200600575A1 (ru) 2006-08-25
CN1729192A (zh) 2006-02-01
WO2002096909A1 (en) 2002-12-05
PL367945A1 (en) 2005-03-07
EA007251B1 (ru) 2006-08-25
LUC00031I2 (instruction) 2017-10-11
ZA200307982B (en) 2004-10-14
EA200301193A1 (ru) 2004-04-29
IS6993A (is) 2003-10-13
NO328578B1 (no) 2010-03-22
KR20060133117A (ko) 2006-12-22
TWI310384B (en) 2009-06-01
UY27317A1 (es) 2003-02-28
JP4381137B2 (ja) 2009-12-09
NO20035201D0 (no) 2003-11-24
EP1666481A3 (en) 2006-11-29
NO20093135L (no) 2003-11-24
MXPA03011062A (es) 2004-03-19
PE20030561A1 (es) 2003-06-23
CR10177A (es) 2008-08-19
AR037321A1 (es) 2004-11-03
IS3023B (is) 2020-08-15
EP1609781B1 (en) 2011-08-10
ECSP034865A (es) 2004-01-28
PL409305A1 (pl) 2014-12-22
EP1609781A1 (en) 2005-12-28
NO2017047I1 (no) 2017-09-08
IL158588A0 (en) 2004-05-12
OA12612A (en) 2006-06-09
EP1666481B1 (en) 2012-09-19
CU23337B7 (es) 2009-01-20
SK288192B6 (sk) 2014-06-03
BG108389A (bg) 2005-01-31
EP1666481A2 (en) 2006-06-07
CL2008000762A1 (es) 2008-07-04

Similar Documents

Publication Publication Date Title
RS52144B (en) OPTICAL RESOLUTION (1-BENZYL-4-METHYLPIPERIDIN-3-YL) -METHYLAMINE AND ITS APPLICATION FOR THE OBTAINING OF PIROLO 2,3-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITOR
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
CA2053253A1 (en) New aryl-and heteroarylethenylene derivatives and process for their preparation
RS50454B (sr) Derivati 2-okso-1-pirolidina, postupak njihovog dobijanja i njihove upotrebe
YU56492A (sh) Derivati hinuklidina
CA2075876A1 (fr) Nouveaux derives d'arylethylamines, leurs procedes de preparation et lescompositions pharmaceutiques qui les contiennent
EA199800882A1 (ru) Производные замешенных индазолов, их применение в качестве ингибиторов фосфодиэстеразы (фдэ) iv и получение фактора некроза опухолей (фно)
ATE117999T1 (de) Zentralnervensystem wirksame chromanderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
CO5271675A1 (es) Derivados de decahidro-isoquinolinas, proceso para su preparacion, composicion y compuestos farmaceuticos que los contienen
MEP24208A (en) Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics
YU46787B (sh) Derivati heteroaril 3-okso-propan-nitrila i postupak za njihovo dobijanje
DK0674621T3 (da) Enantiomerer af carbazolderivater som 5-HT1-lignende agonister
RU94046047A (ru) Производные аминоуксусной кислоты в виде рацемата или d- и l-энантиомеров и их фармацевтически приемлемые соли, способ получения d- и l-энантиомеров производных аминоуксусной кислоты или их фармацевтически приемлемых солей и промежуточные d- и l-энантиомеры аминоуксусной кислоты в виде цинхонидиновой соли
BR9510429A (pt) Composto composição farmacêutica processo para produzir o composto e uso do composto
ATE42292T1 (de) Imidazo(1,2-c)pyrimidine und ihre salze, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
MXPA04002838A (es) Derivados de alquilaminopiridazinona sustituidos, procedimiento para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
ES8500923A1 (es) Procedimiento para la preparacion de derivados de acido fenilacetico
EA200100344A3 (ru) Новые циклобутаиндолкарбоксамидные производные, способ их получения и содержащие их фармацевтические композиции
AU562377B2 (en) 1,1-diphenyl-propanol-derivatives
PL371520A1 (en) New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds
HRP20090054T3 (hr) Derivati piperazina alkilnih oksindola
YU60790A (sh) Postupak za dobijanje 5-fenilpirimidin jedinjenja i njihovih soli
RU94042399A (ru) Получения клавулановой кислоты из соли клавулановой кислоты и амина, соли клавулановой кислоты и амина
AU2003244878A1 (en) Methods of preparation of dehydro-diketopiperazines in liquid phase or of solid supported phase